Nicole E. Putnam

Nicole E. Putnam

Auto-generated profile, based on publicly available information

Nicole E. Putnam

Department of Pathology, University of Maryland School of Medicine, Baltimore, Maryland, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 April 2019 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
NPNicole E Putnam
Nicole E Putnam
LFLaura E Fulbright
Laura E Fulbright
JCJacob M Curry
Jacob M Curry
CFCaleb A Ford
Caleb A Ford
JPJenna R Petronglo
Jenna R Petronglo
JCJim E. Cassat
Jim E. Cassat
Staphylococcus aureus is able to infect virtually all organ systems and is a frequently isolated etiologic agent of osteomyelitis, a common and debilitating invasive infection of bone. Treatment of osteomyelitis requires invasive surgical procedures and prolonged antibiotic therapy, yet is frequently unsuccessful due to extensive pathogen-induced bone damage that can limit antibiotic penetration and immune cell influx to the infectious focus. We previously established that S. aureus triggers profound alterations in bone remodeling in a murine model of osteomyelitis, in part through the production of osteolytic toxins. However, staphylococcal strains lacking osteolytic toxins still incite significant bone destruction, suggesting that host immune responses are also major drivers of pathologic bone remodeling during osteomyelitis. The objective of this study was to identify host immune pathways that contribute to antibacterial immunity during S. aureus osteomyelitis, and to define how these immune responses alter bone homeostasis and contribute to bone destruction. We specifically focused on the interleukin-1 receptor (IL-1R) and downstream adapter protein MyD88 given the prominent role of this signaling pathway in both antibacterial immunity and osteo-immunologic crosstalk. We discovered that while IL-1R signaling is necessary for local control of bacterial replication during osteomyelitis, it also contributes to bone loss during infection. Mechanistically, we demonstrate that S. aureus enhances osteoclastogenesis of myeloid precursors in vitro, and increases the abundance of osteoclasts residing on bone surfaces in vivo. This enhanced osteoclast abundance translates to trabecular bone loss, and is dependent on intact IL-1R signaling. Collectively, these data define IL-1R signaling as a critical component of the host response to S. aureus osteomyelitis, but also demonstrate that IL-1R-dependent immune responses trigger collateral bone damage through activation of osteoclast-mediated bone resorption. Osteomyelitis is a common, debilitating infection of bone that rarely resolves without prolonged antibiotics and invasive surgical procedures. This study explores the role of host inflammation during osteomyelitis. Our findings highlight innate immune responses that are critical for control of S. aureus burdens in bone, prevention of bacterial dissemination, and death. Conversely, these same immune pathways were found to contribute to disease pathogenesis by activating infection-associated bone loss. Such bone loss is associated with detrimental outcomes during osteomyelitis, including pathologic fractures and irreversible changes in bone growth plates. Alterations in bone remodeling that occur during S. aureus osteomyelitis are multifaceted, driven by bacterial toxins and inflammation-mediated changes. We found that inflammation incited by S. aureus in bone contributes to pathologic bone loss. We highlight a mechanism by which S. aureus stimulates formation of bone-resorbing osteoclasts both in vitro and in vivo. Our data illustrate connections between innate immune signaling pathways and bone homeostasis. These connections may be relevant to other autoinflammatory bone and joint conditions characterized by bone loss, such as rheumatoid arthritis. Collectively, this work outlines the fine balance between promotion of bacterial clearance and protection from collateral tissue damage.

13 February 2020 in JCI Insight
Verified
Journal Article
Open access
PDF file
ANAshley N. Nelson
Ashley N. Nelson
WLWen-Hsuan W. Lin
Wen-Hsuan W. Lin
RSRupak Shivakoti
Rupak Shivakoti
NPNicole E. Putnam
Nicole E. Putnam
LMLisa Mangus
Lisa Mangus
DGDiane Griffin
Diane Griffin
Recovery from measles results in life-long protective immunity. To understand induction of long-term immunity, rhesus macaques were studied for 6 months after infection with wild-type measles virus (MeV). Infection caused viremia and rash, with clearance of infectious virus by day 14. MeV RNA persisted in PBMCs for 30–90 days and in lymphoid tissue for 6 months most often in B cells but was rarely detected in BM. Antibody with neutralizing activity and binding specificity for MeV nucleocapsid (N), hemagglutinin (H), and fusion proteins appeared with the rash and avidity matured over 3–4 months. Lymph nodes had increasing numbers of MeV-specific antibody-secreting cells (ASCs) and germinal centers with late hyalinization. ASCs appeared in circulation with the rash and continued to appear along with peripheral T follicular helper cells for the study duration. ASCs in lymph nodes and PBMCs produced antibody against both H and N, with more H-specific ASCs in BM. During days 14–21, 20- to 100-fold more total ASCs than MeV-specific ASCs appeared in circulation, suggesting mobilization of preexisting ASCs. Therefore, persistence of MeV RNA in lymphoid tissue was accompanied by continued germinal center formation, ASC production, avidity maturation, and accumulation of H-specific ASCs in BM to sustain neutralizing antibody and protective immunity.

19 October 2021 in Journal of Clinical Microbiology
Verified
Journal Article
Closed access
NPNicole E. Putnam
Nicole E. Putnam
ALAnna F. Lau
Anna F. Lau
The U.S. Food and Drug Administration (FDA) regulates manufacturing and testing of advanced therapeutic medicinal products (ATMPs) to ensure the safety of each product for human use.

17 November 2022 in Infection and Immunity
Verified
Journal Article
Open access
JPJenna R. Petronglo
Jenna R. Petronglo
NPNicole E. Putnam
Nicole E. Putnam
CFCaleb A. Ford
Caleb A. Ford
VCVirginia Cruz-Victorio
Virginia Cruz-Victorio
JCJacob M. Curry
Jacob M. Curry
JCJim E. Cassat
Jim E. Cassat
Staphylococcus aureus is the major causative agent of bacterial osteomyelitis, an invasive infection of bone. Inflammation generated by the immune response to S. aureus contributes to bone damage by altering bone homeostasis.

20 April 2023 in Journal of Clinical Microbiology
Verified
Journal Article
Closed access
NPNicole E. Putnam
Nicole E. Putnam
JYJung-Ho Youn
Jung-Ho Youn
MWMeghan A. Wallace
Meghan A. Wallace
PLPaul M. Luethy
Paul M. Luethy
CBCarey-Ann D. Burnham
Carey-Ann D. Burnham
ALAnna F. Lau
Anna F. Lau
The Streptococcus bovis group (previously group D streptococci) consists of seven distinct species and subspecies. Definitive identification within the group is important, as certain organisms have been associated with gastrointestinal carcinoma, bacteremia, infective endocarditis, meningitis, biliary tract disease, and carcinoma, among others.

29 August 2022 in Infectious Disease Reports
Verified
Journal Article
Open access
PDF file
JDJames Doub
James Doub
Sumon NandiSumon Nandi
Sumon Nandi
NPNicole Putnam
Nicole Putnam
Background: The treatment of hardware infections often utilizes chronic oral suppression antibiotics to prevent infection recurrence. However, when methicillin-resistant Staphylococcus aureus and other bacteria are non-susceptible to doxycycline, limited oral antibiotic options can be available that do not cause significant side effects and drug–drug interactions. Consequently, the purpose of this study was to evaluate the ability of Gram-positive clinical prosthetic joint infection isolates that were non-susceptible to doxycycline and to retain susceptibility to minocycline. Methods: Twenty-six Gram-positive prosthetic joint infection isolates that were not susceptible to doxycycline were evaluated for retained minocycline susceptibility with the use of minocycline gradient diffusion test strips. Results: All five of the coagulase-negative staphylococcal isolates and eight of the eleven methicillin-resistant S. aureus isolates were susceptible to minocycline, despite being doxycycline non-susceptible. None of the five Enterococcus faecium PJI isolates retained susceptibility to minocycline and only two of the five E. faecalis isolates (n = 5) were susceptible to minocycline. Conclusions: The findings have direct clinical implications supporting minocycline susceptibility testing for patients with PJI and other hardware-associated infections, which have isolates that are doxycycline non-susceptible to thereby provide alternative suppression antibiotic options.